Method for treating or preventing inflammation

ABSTRACT

The present invention relates to an extract obtained from or obtainable from Rubus idaeus, a composition comprising an extract obtained from or obtainable from Rubus idaeus, processes for providing such an extract, and methods and uses relating to such extracts. In particular, the present invention relates to an extract or composition for use in treating or preventing inflammation, such as arthritis and joint inflammation.

This application is a continuation of co-pending U.S. Ser. No.16/472,088, filed Jun. 20, 2019, which is a United States national stageapplication under 35 U.S.C. § 371 of PCT Application No.PCT/EP2017/084266, filed Dec. 21, 2017, which claims the prioritybenefit of Great Britain Patent Application No. 1622161.6, filed Dec.23, 2016.

The present invention relates to an extract obtained from or obtainablefrom Rubus idaeus, a composition comprising an extract obtained from orobtainable from Rubus idaeus, processes for providing such an extract,and uses of such extracts. In particular, the present invention relatesto an extract or composition for use in treating or preventinginflammation, such as arthritis and joint inflammation.

The listing or discussion of an apparently prior-published document inthis specification should not necessarily be taken as an acknowledgementthat the document is part of the state of the art or is common generalknowledge.

Inflammation is a complex biological response of tissues to harmfulstimuli, such as pathogens, tissue damage, or irritants. It is aprotective attempt by the tissue to remove the injurious stimuli as wellas initiate the healing process for the tissue.

In a typical inflammation response, a cascade of biochemical eventspropagates and matures the inflammation response. Circulating peripheralblood mononuclear cells (PBMCs) such as leukocytes are important cellsin these biochemical cascades. These cells express a range ofpathogen-recognition receptors (PRRs) which recognize highly conservedpathogen-associated molecular patterns (PAMPs) present with bacteria,viruses, fungi, mycoplasma, and parasitic protozoa.

Several biochemical molecules may be involved with inflammation or animmune response. For example, tumor necrosis factor-alpha (TNF-α) is acytokine involved in systemic inflammation and is used in the initiationof inflammation. Various interleukins may also be involved such asinterleukin 8 (IL-8), which is a chemoattractant for certaininflammatory molecules and induces chemotaxis in its target cells,interleukin 4 (IL-4), which induces differentiation of naïve helper Tcells to Th2 cells and the stimulation of B-cells, interleukin 2 (IL-2),which is a cytokine that attracts lymphocytes or leukocytes, interleukin6 (IL-6), which is a cytokine involved in acute phase protein synthesisand the production of neutrophils in the bone marrow, interleukin 10(IL-10) which is an anti-inflammatory cytokine and interleukins-1 alpha(IL-1α) and beta (IL-1β), which are cytokines involved in the initialproduction of inflammation.

Abnormalities associated with inflammation comprise a large, unrelatedgroup of disorders which underlie a variety of human diseases(inflammatory disorders). Examples of diseases with an inflammatoryaspect include (but are not limited to) asthma, autoimmune disease,glomerulonephritis, allergy (hypersensitivities), inflammatory boweldiseases, reperfusion injury, arthritis, tumors, neurologicalinflammation and transplant rejection.

The term “inflammation” as used herein, may refer to acute inflammationand/or chronic inflammation.

Attempts to treat inflammation have met with limited success. This isdue, in part, to the fact that the etiology of inflammation is a complexresponse based in part on the various inflammation inducing moleculesand the multitude of inflammation mediating and sensitizing moleculesthat appear to elicit inflammation via redundant mechanism.

Many anti-inflammatory drugs currently in use, also inhibit regulatoryloops that release endogenous anti-inflammatory molecules. For example,NSAIDs reduce inflammation by blocking the enzymatic activity ofcyclooxygenase, a key enzyme that catalyzes the conversion ofarachidonic acid to prostaglandins and leukotrienes. Thus, NSAIDs reduceinflammation by preventing the synthesis of all prostaglandins. However,NSAIDs not only prevent the synthesis of proinflammatory prostaglandins,these compounds also prevent the synthesis of anti-inflammatoryprostaglandins. Hence, NSAIDs have limited success as they blockendogenous anti-inflammatory response, which in some instances mayprolong chronic inflammation. Therefore, compounds, compositions, uses,and methods preferentially inhibiting pro-inflammatory responses wouldbe highly desirable for the treatment of inflammation.

The present inventors have surprisingly and unexpectedly found thatextracts obtained from Rubus idaeus, such as from the leaves of Rubusidaeus, possess potent anti-inflammatory activity, including activitywhich reduces and/or inhibits the release of at least oneproinflammatory cytokine. These effects suggest that extracts obtainedfrom Rubus idaeus, such as from the leaves of Rubus idaeus, may havenumerous therapeutic and non-therapeutic uses (e.g. cosmetic uses), suchas treating or preventing inflammation.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts the paw thickness of the treated animals based on theprocedure detailed in Example 4. P<0.05 for PBS/mBSA vs D120/mBSA;#P<0.05 for PBS/PBS vs. PBS/m BSA.

FIG. 2 depicts the plasmatic level of IL-6, IL-1b and TNF-α in treatedanimals based on the procedure detailed in Example 5.*P<0.05 Vs PBS/PBS.

FIG. 3 depicts the plasmatic level of bioactive lipids in treatedanimals based on the procedure detailed in Example 6. P<0.05 VsD120/mBSA.

FIG. 4 depicts Granzyme B inhibition for the extract of the inventioncompared to a positive and negative control.

FIG. 5 depicts Granzyme B inhibition for an extract of the inventionobtained using water only as the solvent.

FIG. 6 depicts Granzyme B inhibition for an extract of the inventionobtained using a 30% ethanol solvent.

FIG. 7 depicts the histological results of right leg tissues based onthe procedure detailed in Example 7.*P<0.05 vs PBS/PBS; #P<0.05 vsPBS/mBSA.

DETAILED DESCRIPTION OF THE INVENTION

According to the present invention, there is provided an extractobtained from or obtainable from Rubus idaeus. For example, the extractmay be obtained from or obtainable from Rubus idaeus in the absence ofother plants of the Rubus species. This extract may be referred tohereinafter as the “extract of the invention”.

Typically, the extract of the invention may be an extract obtained fromor obtainable from Rubus idaeus, in particular from the aerial part ofthe plant, such as the stems and/or leaves. For instance, in someaspects, the extract of the invention may not be obtained from orobtainable from the seeds and/or fruit of Rubus idaeus. For example, theextract may be obtained from or obtainable from the leave of Rubusidaeus only.

As will be appreciated by the person skilled in the art, as used hereinthe term “obtainable from” means that the extract may be obtained from aplant or may be isolated from the plant, or may be obtained from analternative source, for example by chemical synthesis or enzymaticproduction. Whereas the term “obtained” as used herein, means that theextract is directly derived from the plant source.

The extract obtained from or obtainable from Rubus idaeus may be anaqueous extract, an alcohol extract or an organic extract. In someinstances, an aqueous extract obtained from Rubus idaeus and an alcoholextract obtained from Rubus idaeus may be combined to form a mixed Rubusidaeus extract. The ratio of aqueous extract to alcohol extract in themixed Rubus idaeus extract may be from 20:1 to 1:20 or from 1:10 to10:1, such as from 1:5 to 5:1.

The term “aqueous extract” as used herein, refers to the extractobtained from Rubus idaeus when the extraction from the plant (such asthe aerial part of plant, for example the leaves) has been performedusing water as the only solvent.

The term “alcohol extract” as used herein, refers to the extractobtained from Rubus idaeus when the extraction from the plant (such asthe aerial part of plant, for example the leaves) has been performedusing an alcohol as the solvent. The alcohol solvent may consist of onlyalcohol (e.g. 100% alcohol), for example 100% ethanol, or may be amixture of an alcohol and water (hydro-alcoholic solvent), for example,a mix of ethanol and water (hydro-ethanolic solvent), for example, fromabout 1% to about 99% alcohol (e.g. ethanol) in water. In someinstances, the alcohol solvent may comprise or consist of from about 30%ethanol to about 70% ethanol, i.e. have a ratio of ethanol/water of fromabout 30/70 to about 70/30 v/v. Where the extract has been obtainedusing a hydro-alcoholic solvent it is typically referred to as thehydro-alcoholic extract.

The term “organic extract” as used herein, refers to the extractobtained from Rubus idaeus when the exaction from the plant (such as theaerial part of the plant) has been performed using an organic solventthat is not an alcohol as the solvent. For example, the organic solventmay be selected from the group consisting of acetic acid, acetone,acetonitrile, benzene, 1-butanol, 2-butanol, 2-butanone, carbontetrachloride, chlorobenzene, chloroform, cyclohexane,1,2-dichloroethane, diethylene glycol, diethyl ether, diglyme(diethylene glycol, dimethyl ether), 1,2-dimethoxy-ethane (glyme, DME),dimethyl-formamide (DMF), dimethyl sulfoxide (DMSO), 1,4-dioxane, ethylacetate, ethylene glycol, glycerin, heptane, hexamethylphosphoramide(HMPA), hexamethylphosphorous, triamide (HMPT), hexane, methyl t-butyl,ether (MTBE), methylene chloride, N-methyl-2-pyrrolidinone (NMP),nitromethane, pentane, petroleum ether (ligroine), 1-propanol,2-propanol, pyridine, tetrahydrofuran (THF), toluene, triethyl amine,o-xylene, m-xylene and p-xylene.

For example, the extract of the invention may be a hydro-ethanolicextract obtained or obtainable from the leaves of Rubus idaeus.

The extract obtained from Rubus idaeus may comprise:

-   -   (i) from about 1% to about 40% by weight of the extract, such as        from about 2% to about 20% or from about 2% to about 15% by        weight of phenolic compounds including from about 1% to about        10% by weight of the extract, such as from about 2% to about 8%        by weight of the extract sanguiin H6;    -   (ii) from about 0.5% to about 7% by weight of the extract, such        as from about 1% to about 4% by weight of the extract of        hydroxycimmanic acid and ellagic compounds; and    -   (iii) from about 1% to about 15% by weight of the extract, such        as from about 2% to about 6% by weight of the extract of        flavonoid compounds.

For example, the aqueous extract obtained from Rubus idaeus maycomprise:

-   -   (i) from about 1.5% to about 40% by weight of the extract, such        as from about 2.5% to about 15% or from about 2.5% to about 10%        by weight of the extract of phenolic compounds;    -   (ii) from about 0.5% to about 6% by weight of the extract, such        as from about 1% to about 1.5% by weight of the extract of        hydroxycimmanic acid and ellagic compounds; and    -   (iii) from about 1% to about 15% by weight of the extract, such        as from about 2% to about 6% by weight of the extract of        flavonoid compounds.

For example, the ethanol extract obtained from Rubus idaeus, such asfrom a 30% alcohol extract, may comprise:

-   -   (i) from about 1% to about 40% by weight of the extract, such as        from about 7.5% to about 20% or from about 10% to about 15% by        weight of the extract of phenolic compounds including from about        1% to about 10% by weight of the extract, such as from about 2%        to about 8% by weight of the extract sanguiin H6;    -   (ii) from about 0.5% to about 7% by weight of the extract, such        as from about 1% to about 4% by weight of the extract of        hydroxycimmanic acid and ellagic compounds; and    -   (iii) from about 1% to about 15% by weight of the extract, such        as from about 2.5% to about 6% by weight of the extract of        flavonoid compounds.

The extract obtained from Rubus idaeus may also comprise totalpolyphenols in an amount from about 10% to about 30%, such as from about15% to about 25% by weight of the extract as calculated using the FolinCiocalteu method.

Phenolic compounds in the extract obtained from Rubus idaeus include,but are not limited to, compounds from the ellagitannin family,geraniin, sanguiin H10, lambertianin C and sanguiin H6.

In a particular instance, the extract of the invention is ahydro-ethanolic extract (such as a hydro-ethanolic extract obtainedusing ethanol/water in a ratio of from about 30/70 to about 70/30 v/v)from the leaves of Rubus idaeus. It has been surprisingly found by thepresent inventors that such an extract contains advantageouscombinations of certain active compounds.

For example, a hydro-ethanolic extract of the invention as previouslydefined has been found to contain high concentrations (such as greaterthan 0.2%, or greater than 0.4%) of sanguiin H6, which has been found tohave Granzyme B inhibition, which has been found to be involved inconditions such as rheumatoid arthritis and/or osteoarthritis.

Hydroxycimmanic acid and ellagic compounds in the extract obtained fromRubus idaeus include, but are not limited to, chlorogenic acid,p-coumaric acid and ellagic acid.

Flavonoid compounds in the extract obtained from Rubus idaeus include,but are not limited to, quercetin-3-O-xyl-glucuronide, hyperoside,kaempferol glucoside, quercetin-3-O-glucuronide, quercetin (C₂₇H₂₈O₁₆),kaempferol, kaempferol-3-O-glucuronide and kaempferol-3-O-galactoside.

Unless otherwise stated herein, the weight percentages listed are basedon the total weight of extract obtained either in dry or liquid form.For example, in some aspects, the weight percentages listed are based onthe total weight of the dry extract.

For the avoidance of doubt, preferences, options, particular featuresand the like indicated for a given aspect, feature or parameter of theinvention should, unless the context indicates otherwise, be regarded ashaving been disclosed in combination with any and all other preferences,options particular features and the like as indicated for the same orother aspects, features and parameters of the invention.

The term “about” as used herein, e.g. when referring to a measurablevalue (such as an amount or weight of a particular component in thereaction mixture), refers to variations of ±20%, ±10%, ±5%, ±1%, ±0.5%,or, particularly, ±0.1% of the specified amount.

The skilled person will understand that the extract of the invention maybe provided in solid form or in liquid form. By solid form, it isincluded that the extract may be provided as an amorphous solid, or as acrystalline or part-crystalline solid.

Compositions and Administration

The extract of the invention may be provided in the form of apharmaceutical composition (which may also be referred to as apharmaceutical formulation), veterinary composition or functional foodcomposition, such as a food, feed or pet food or a food, feed or petfood supplement, comprising the extract of the invention and optionallya pharmaceutically or veterinary acceptable excipient or (functional)food acceptable ingredient, as appropriate.

Typically, the extract of the invention is provided in a composition inthe absence of other plant extracts. For example, in the absence ofextracts obtained from or obtainable from other Rubus species and/orother berry extracts, such as extracts obtained from or obtainable fromblueberry, blackberry, asaiberry, raspberry, bilberry, cranberry, blackchokeberry, (Aronia fruit), sesame fruit, shopberry and strawberry.

As used herein, references to pharmaceutically or veterinary acceptableexcipients may refer to pharmaceutically or veterinary acceptableadjuvants, diluents and/or carriers as known to those skilled in theart.

Food acceptable ingredients include those known in the art (includingthose also referred to herein as pharmaceutically acceptable excipients)and can be natural or non-natural, i.e. their structure may occur innature or not. In certain instances, they can originate from naturalcompounds and be later modified (e.g. maltodextrin).

By “pharmaceutically or veterinary acceptable” we mean that theadditional components of the composition are generally safe, non-toxic,and neither biologically nor otherwise undesirable. For example, theadditional components are generally sterile and pyrogen free. Suchcomponents must be “acceptable” in the sense of being compatible withthe extract of the invention and not deleterious to the recipientsthereof. Thus, “pharmaceutically acceptable excipients” includes anycompound(s) used in forming a part of the formulation that is intendedto act merely as an excipient, i.e. not intended to have biologicalactivity itself.

The skilled person will understand that extracts of the invention (e.g.in the form of compositions, such as pharmaceutical or veterinarycompositions) may be administered to a patient or subject (e.g. a humanor animal patient or subject) by any suitable route, such as by theoral, rectal, nasal, pulmonary, buccal, sublingual, transdermal,intracisternal, intraperitoneal, and parenteral (including subcutaneous,intramuscular, intrathecal, intravenous and intradermal) route.

In particular, extracts of the invention may be administered orally. Insuch instances, pharmaceutical or veterinary compositions according tothe present invention may be specifically formulated for administrationby the oral route.

Pharmaceutical or veterinary compositions for oral administrationinclude solid dosage forms such as hard or soft capsules, tablets,troches, dragees, pills, lozenges, powders and granules. Whereappropriate, they can be prepared with coatings such as entericcoatings, or they can be formulated so as to provide controlled releaseof the active ingredient, such as sustained or prolonged release,according to methods well known in the art.

Liquid dosage forms for oral administration include solutions,emulsions, aqueous or oily suspensions, syrups and elixirs.

Compositions (e.g. pharmaceutical or veterinary or food compositions)described herein, such as those intended for oral administration, may beprepared according to methods known to those skilled in the art, such asby bringing the components of the composition into admixture.

The compositions of the invention may contain one or more additionalcomponents as food ingredients or pharmaceutical components, such assweetening agents, flavouring agents, colouring agents and preservingagents. The compositions of the invention may contain the activeingredient(s) in admixture with non-toxic pharmaceutically acceptableexcipients (or ingredients) which are suitable for the manufacture oftablets. These excipients (or ingredients) may, for example, be: inertdiluents, such as calcium carbonate, sodium carbonate, lactose, calciumphosphate or sodium phosphate; granulating and disintegrating agents,for example, corn starch, maltodextrin or alginic acid; binding agents,for example, starch, gelatine or acacia; and lubricating agents, forexample magnesium stearate, stearic acid or talc.

The compositions of the invention may be uncoated or they may be coatedby known techniques to delay disintegration and absorption in thegastrointestinal tract and thereby provide a sustained action over alonger period. For example, a time delay material such as glycerylmonostearate or glyceryl distearate may be employed.

Suitable pharmaceutical or veterinary carriers include inert soliddiluents or fillers, sterile aqueous solutions and various organicsolvents. Examples of solid carriers are lactose, terra alba, sucrose,cyclodextrin, maltodextrin, dextrin, talc, gelatine, agar, pectin,acacia, magnesium stearate, magnesium hydroxide; stearic acid, arabicgum, modified starch and lower alkyl ethers of cellulose, saccharose,silicon dioxide. Examples of liquid carriers are syrup, vegetables oils,phospholipids, fatty acids, fatty acid amines, polyoxyethylene andwater. Moreover, the carrier or diluent may include any sustainedrelease material known in the art, such as glyceryl monostearate orglyceryl distearate, alone or mixed with a wax.

Moreover, the carrier or diluent may include any sustained releasematerial known in the art, such as glyceryl monostearate or glyceryldistearate, alone or mixed with a wax.

The term “carrier” as used herein, may refer to a natural product or aproduct originating from nature that has been transformed or modified sothat it is distinct from the natural product from which it originated.

In an aspect of the invention, the extract of the invention is providedin a composition comprising maltodextrin and/or silicon dioxide.

Depending on the disorder, and the subject, to be treated, as well asthe route of administration, extracts of the invention may beadministered at varying doses (i.e. therapeutically effective doses, asadministered to a patient in need thereof). In this regard, the skilledperson will appreciate that the dose administered to a mammal,particularly a human, in the context of the present invention should besufficient to effect a therapeutic response in the mammal over areasonable timeframe. One skilled in the art will recognize that theselection of the exact dose and composition and the most appropriatedelivery regimen will also be influenced by inter alia thepharmacological properties of the formulation, the nature and severityof the condition being treated, and the physical condition and mentalacuity of the recipient, as well as the age, condition, body weight, sexand response of the patient to be treated, and the stage/severity of thedisease.

The pharmaceutical or veterinary or food compositions may comprise anextract obtained from or obtainable from Rubus idaeus in atherapeutically effective amount. As used herein, the term “effectiveamount” is synonymous with “therapeutically effective amount”,“effective dose”, or “therapeutically effective dose” and when used inreference to treating inflammation refers to the minimum dose of theextract of the invention necessary to achieve the desired therapeuticeffect and includes a dose sufficient to reduce a symptom associatedwith inflammation. Effectiveness in treating inflammation can bedetermined by observing an improvement in an individual based upon oneor more clinical symptoms, and/or physiological indicators associatedwith the condition. An improvement in inflammation also can be indicatedby a reduced need for a concurrent therapy.

The appropriate effective amount of the extract of the invention to beadministered to an individual for a particular inflammation can bedetermined by a person of ordinary skill in the art by taking intoaccount factors, including, without limitation, the type ofinflammation, the location of the inflammation, the cause of theinflammation, the severity of the inflammation, the degree of reliefdesired, the duration of relief desired, the particular dosage ofextract of the invention that is used, the rate of excretion of theextract of the invention used, the pharmacodynamics of the extract ofthe invention used, the nature of other compounds that may be includedin the composition, the particular formulation, the particular route ofadministration, the particular characteristics, history and risk factorsof the patient, such as, e.g., age, weight, general health and the like,or any combination thereof.

Additionally, where repeated administration of the extract of theinvention is used, an effective amount of the extract of the inventionwill further depend upon factors, including, without limitation, thefrequency of administration, the half-life of the extract of theinvention, or any combination thereof.

In the use or method of the invention the extract of the invention maybe administered in an amount of from about 100 mg/day to about 2000mg/day, or from about 500 mg/day to about 1500 mg/day, or about 1000mg/day. If the extract is administered in the form of a pharmaceuticalor veterinary or food, feed or pet food supplement or food, feed or petfood composition comprising the extract, the extract would be present inan amount to provide the above dosages of extract. For example, the foodcomposition may comprise from about 100 mg to about 2000 mg or fromabout 500 mg to about 1500 mg, or about 1000 mg of the extract of theinvention and the pharmaceutical composition may comprise 10 mg, 20 mg,30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 100 mg, 250 mg, 500 mg, 1000mg, 1500 mg or 2000 mg of the extract of the invention, such that thefood composition or the pharmaceutical or veterinary composition may beadministered one or more times per day in order to provide from about100 mg to about 2000 mg/day or from about 500 mg to about 1500 mg/day,or about 1000 mg/day of the extract of the invention.

When included within a composition (e.g. a pharmaceutical or veterinarycomposition or a food composition), the extract is typically present inan amount from about 1% by weight to about 100% by weight, for example,from about 10% by weight to about 90% by weight or about 20% by weightto about 80% or from about 30% by weight to about 70% or from about 40%by weight to about 60% by weight.

Pharmaceutical or veterinary or food compositions of the invention mayconsist of or consist essentially of the extract of the invention andpharmaceutical or veterinary or food composition.

For the avoidance of doubt, in this specification when we use the term“comprising” or “comprises” we mean that the extract or compositionbeing described must contain the listed ingredient(s) but may optionallycontain additional ingredients. When we use the term “consistingessentially of” or “consists essentially of” we mean that the extract orcomposition being described must contain the listed ingredient(s) andmay also contain small (for example up to 5% by weight, or up to 1% or0.1% by weight) of other ingredients provided that any additionalingredients do not affect the essential properties of the extract orcomposition. When we use the term “consisting of” or “consists of” wemean that the extract or composition being described must contain thelisted ingredient(s) only.

Processes for Obtaining Extracts

The extract of the invention may be obtained from or obtainable fromRubus idaeus, in particular, from the arieal parts of Rubus idaeus, suchas the stem and/or leaves using separation techniques that select forthe required extract, which may be determined by those skilled in theart. Seeds and/or fruit may also be present, although it is preferredthat that aerial parts of Rubus idaeus not including seeds and/or fruitare used.

Typically, the extract of the invention may be obtained by extractionand isolation processes as generally described below, or routinemodifications thereof.

For example, the process for providing an extract obtained from Rubusidaeus may be described as comprising the steps of:

(a) grinding the aerial part of Rubus idaeus (such as the stem and/orleaves) into particles;

(b) contacting the ground particles with a solvent mixture;

(c) separating the ground particles from the solvent mixture, forexample by filtration (and optionally repeating step (b) with theseparated particles);

(d) evaporating the solvent mixture; and optionally

(e) drying the product obtained in step (d).

Typically, Rubus idaeus, such as the arieal part of Rubus idaeus, isground into particles with a diameter in a range from about 0.1 mm toabout 30 mm, such as from about 0.5 mm to about 15 mm or from about 1 mmto about 10 mm, e.g. from about 1.5 mm to about 5 mm. Any suitablegrinding technique known in the art may used, such as a mesh.

Particular solvents that may be used in the contacting (extraction)process include water, alcohol, alcohol/water mixtures (hydro-alcoholicsolvents), ethyl acetate, acetone, hexane or any other solvent that maytypically be used for extraction. For example, the extraction solventmay be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% alcohol in water,such as 30% alcohol in water. Particular alcohols that may be mentionedinclude ethanol (EtOH) and methanol (MeOH). The solvents used may or maynot be food grade.

In some instances, the hydro-alcoholic solvent may comprise or consistof from about 30% ethanol to about 70% ethanol, i.e. have a ratio ofethanol/water of from about 30/70 to about 70/30 v/v.

The temperature of the contacting (extraction) step (step (b)) willdepend on the solvent used and may be in a range of from about 20° C. toabout 150° C. For example, the temperature for extraction may be in arange of from about 50° C. to about 70° C. The temperature forextraction may also be a temperature at which the solvent used for theextraction will reflux.

The contacting (extraction) of Rubus idaeus may be performed with orwithout agitation, such as by maceration.

The contacting (extraction) of Rubus idaeus may be performed with orwithout pressure.

Any suitable extraction apparatus may be used. For example, the extractof the invention may be extracted using Soxhlet apparatus.

Typically, the ratio of plant material to solvent used in the extractionprocess varies from about 1:1 to about 1:30 on a gram to millilitrebasis, such as from about 1:3 to about 1:15 e.g. 1:5 or 1:10 w/v.

The contacting (extracting) period (i.e. the period during which theplant material is in contact with the solvent) is typically from about0.5 hours to about 24 hours, such as from about 1 hour to about 12hours. Any un-dissolved plant material may be removed from the solvent,for example, by filtration, and re-dissolved in the solvent. Thecontacting step may be then be repeated.

The contacting (extraction) step may be repeated more times as deemednecessary. For example, the contacting step may be repeated two, threeor four times.

After the plant materials and solvent have been contacted, the solventmay be separated from any un-dissolved plant material (for example, byfiltration) and the solvent (filtrate) concentrated (i.e. the solvent isremoved) until a solid component has formed. For example, the solventmay be concentrated until all the solvent has been removed and onlysolid extract remains. Typically, the solvent (filtrate) is concentrated(for example, by rotary evaporation) to about 30% to about 70% DM (DryMaterial, Dried Matter or Dry Matter) such as about 50% DM. Theresulting solid may be referred to as the “native extract”.

The native extract may then be further dried to a % DM of about 90% toabout 99%, such as about 97%. Drying processes that may be used include,but are not limited to, atomization, air drying, ovendrying, and sundrying. The drying may be done with or without a carrier, such as thosedescribed previously. For example, the drying may be done usingmaltodextrine as a carrier.

By the process of extraction, certain active compounds within theextract are increased and other compounds decreased when compared to theactive compounds found in the originating plant.

The present inventors have found that there is a significant industrialand economic advantage in extracting Rubus ideaus in two stages. Byincluding an addition extraction stage, the mass yield is increasedwithout compromising the percentage of active compounds see table belowfor example.

When using two extraction stages, the mass yield of Rubus idaeus extractcan be increased by 1.5 compared to when only one extraction is used,while the polyphenol yield is maintained at the same level.

H₂0 100% Water Water EtOH Etoh Etoh two 100% 1^(st) 100% 2^(nd) 30% two30% 1^(st) 30% 2^(nd) samples extractions extraction extractionextractions extraction extraction Mass yield (%) 29.2 19.20 10 27.9 19.48.5 TOTAL 23.48 23.42 23.68 27.23 27.15 27.52 Polyphenols by FolinCiocalteu (%)

Typically, the resulting solid component may comprise from about 1% toabout 40% by weight, such as from about 2% to about 20% or from about 2%to about 15% by weight by weight of phenolic compounds, from about 0.5%to about 7% by weight, such as from about 1% to about 4% by weight ofhydroxycimmanic acid and ellagic compounds and from about 1% to about15% by weight, such as from about 2% to about 6% by weight of flavonoidcompounds.

The extract obtained from Rubus idaeus may also comprise polyphenols inan amount from about 10% to about 30%, such as from about 15% to about25% by weight of the extract as calculated using the Folin Ciocalteumethod.

Typically, in the process for providing an extract obtained from Rubusidaeus (i.e. steps (a) to (e) as described above): the ground particleshave a diameter from about 0.1 mm to 30 mm; and/or the temperature isfrom about 20° C. to about 150° C.; and/or the ratio of ground particlesto solvent mixture is from about 1 g to 1 ml to about 1 g to 8 ml;and/or the ground particles are in contact with the solvent mixture fromabout 0.5 hours to about 24 hours; and/or the solvent mixture is water,a water-alcohol mixture or alcohol.

The terms “isolated” and “purified” as used herein refer to the extractof the invention or compounds within the extract of the invention beingseparated from at least one other component (e.g. a polypeptide orcellulose derivative) present with the components of the extract in thenatural source, e.g. the aerial parts of Rubus idaeus. For example, theextract or compounds within the extract may be provided in pure form orin the presence of a solvent, buffer, ion, or other component normallypresent in a solution of the same.

Thus, the terms “isolated” and “purified” do not refer to the extract orcompounds within the extract before they have been extracted from Rubusidaeus. Similarly, the term extract refers to components of the naturalmaterial having been obtained through a process of extraction, ratherthan those components before they have been extracted from Rubus idaeus(e.g. when present in the aerial parts of Rubus idaeus).

The extract of the invention as obtained from such processes may be:

-   -   substantially free of other plant material (e.g. free of plant        cellulose);    -   substantially free of plant cells; and/or    -   substantially free of plant cellular matter.

As used herein, references to a material being “substantially free” ofanother material may refer to the material consisting of less than 1% byweight (e.g. less than 0.1%, such as less than 0.01% or less than0.001%, by weight) of that other material.

The extract of the invention as may be an extract obtained from (orobtainable by) a process of the invention as previously described.

Therapeutic Uses

The extract of the invention may have particular biological effects,which may be useful in the treatment of medical conditions. Thus,according to the present invention, there is provided the use of theextract of the invention for use in treating or preventing inflammation.

The extract of the invention may reduce and/or inhibit the release of atleast one proinflammatory cytokine, such as TNF-alpha, IL-6 and IL-1beta(as shown in FIG. 2).

The extract of the invention may increase levels of specialisedpro-resolving mediators derived from arachidonic acid, eicosapentaenoicacid and/or docosahexaenoic acid (as shown in FIG. 3).

The extract of the invention may inhibit Granzyme B activity (forexample, as shown in FIGS. 4, 5 and 6).

Granzyme B is a serine protease that induces cell apoptosis and isinvolved in apotosis of chondrocytes. Granzyme B also induces cartilageproteoglycan degradation. Serum levels of Granzyme B are increased inconditions such as rheumatoid arthritis and osteoarthritis. GranzymeB-positive cells are present at the invasive front of the pannus tissuein patients with rheumatoid arthritis.

The invention also provides a composition comprising an extract obtainedfrom or obtainable from Rubus idaeus for use in treating or preventinginflammation, such as inflammation resulting from rheumatoid arthritisand/or osteoarthritis.

There is also provided the use of an extract obtained from or obtainablefrom Rubus idaeus in the manufacture of a medicament for treating orpreventing inflammation, such as inflammation resulting from rheumatoidarthritis and/or osteoarthritis.

There is also provided a method for treating or preventing inflammation,such as inflammation resulting from rheumatoid arthritis and/orosteoarthritis, comprising the administration of a therapeuticallyeffective amount of an extract obtained from or obtainable from Rubusidaeus or a composition comprising an extract obtained from Rubus idaeusto a subject in need thereof.

Inflammation symptoms can be associated with a large, unrelated group ofdisorders which underlay a variety of diseases and disorders. The immunesystem is often involved with inflammatory disorders, demonstrated inboth allergic reactions and some myopathies, with many immune systemdisorders resulting in abnormal inflammation. Non-immune diseases withetiological origins in inflammatory processes that the extract of theinvention may be used to treat or prevent include, but are not limitedto cancer, atherosclerosis, and ischaemic heart disease. Non-limitingexamples of disorders exhibiting inflammation as a symptom include, butare not limited to, acne, acid reflux/heartburn, age related maculardegeneration (AMD), allergy, allergic rhinitis, Alzheimer's disease,amyotrophic lateral sclerosis, anemia, appendicitis, arteritis,arthritis, asthma. atherosclerosis, autoimmune disorders, balanitis,blepharitis, bronchiolitis, bronchitis, a bullous pemphigoid, burn,bursitis, cancer, cardiac arrest, carditis, celiac disease, cellulitis,cervicitis, cholangitis, cholecystitis, chorioamnionitis, chronicobstructive pulmonary disease (COPD), cirrhosis, colitis, congestiveheart failure, conjunctivitis, cyclophosphamide-induced cystitis, cysticfibrosis, cystitis, common cold, dacryoadenitis, dementia, dermatitis,dermatomyositis, diabetes, diabetic neuropathy, diabetic retinopathy,diabetic nephropathy, diabetic ulcer, digestive system disease, eczema,emphysema, encephalitis, endocarditis, endometritis, enteritis,enterocolitis, epicondylitis, epididymitis, fasciitis, fibromyalgia,fibrosis, fibrositis, gastritis, gastroenteritis, gingivitis,glomerulonephritis, glossitis, heart disease, heart valve dysfunction,hepatitis, hidradenitis suppurativa, Huntington's disease,hyperlipidemic pancreatitis, hypertension, ileitis, infection,inflammatory bowel disease, inflammatory cardiomegaly, inflammatoryneuropathy, insulin resistance, interstitial cystitis, interstitialnephritis, iritis, ischemia, ischemic heart disease, keratitis,keratoconjunctivitis, laryngitis, lupus nephritis, mastitis,mastoiditis, meningitis, metabolic syndrome (syndrome X), a migraine,multiple sclerosis, myelitis, myocarditis, myositis, nephritis,non-alcoholic steatohepatitis, obesity, omphalitis, oophoritis,orchitis, osteochondritis, osteopenia, osteomyelitis, osteoporosis,osteitis, otitis, pancreatitis, Parkinson's disease, parotitis, pelvicinflammatory disease, pemphigus vularis, pericarditis, peritonitis,pharyngitis, phlebitis, pleuritis, pneumonitis, polycystic nephritis,proctitis, prostatitis, psoriasis, pulpitis, pyelonephritis,pylephlebitis, renal failure, reperfusion injury, retinitis, rheumaticfever, rhinitis, salpingitis, sarcoidosis, sialadenitis, sinusitis,spastic colon, stenosis, stomatitis, stroke, surgical complication,synovitis, tendonitis, tendinosis, tenosynovitis, thrombophlebitis,tonsillitis, trauma, traumatic brain injury, transplant rejection,trigonitis, tuberculosis, tumor, urethritis, ursitis, uveitis,vaginitis, vasculitis, and vulvitis.

Inflammation as used in the present invention may also comprise tissueinflammation. Tissue inflammation is an inflammation that is confined toa particular tissue or organ. Tissue inflammation that the extract ofthe invention may be used to treat or prevent includes, but is notlimited to skin inflammation, muscle inflammation, tendon inflammation,ligament inflammation, bone inflammation, cartilage inflammation, lunginflammation, heart inflammation, liver inflammation, pancreaticinflammation, kidney inflammation, bladder inflammation, stomachinflammation, intestinal inflammation, brain inflammation.

Inflammation may also comprise systemic inflammation. Although theprocesses involved are typically identical to tissue inflammation,systemic inflammation is not confined to a particular tissue but in factoverwhelms the body, involving the endothelium and other organ systems.When it is due to infection, the term sepsis is applied, with the termsbacteremia being applied specifically for bacterial sepsis and viremiaspecifically to viral sepsis. Vasodilation and organ dysfunction areserious problems associated with widespread infection that may lead toseptic shock and death.

Inflammation as used in the present invention may also comprise anautoimmune disorder. Autoimmune diseases can be broadly divided intosystemic and organ-specific autoimmune disorders, depending on theprincipal clinico-pathologic features of each disease. Systemicautoimmune diseases include, without limitation, systemic lupuserythematosus (SLE), Sjogren's syndrome, Scleroderma, rheumatoidarthritis and polymyositis. Local autoimmune diseases may beendocrinologic (Diabetes Mellitus Type 1, Hashimoto's thyroiditis,Addison's disease etc.), dermatologic (pemphigus vulgaris), hematologic(autoimmune haemolytic anemia), neural (multiple sclerosis) or caninvolve virtually any circumscribed mass of body tissue. Types ofautoimmune disorders include, without limitation, acute disseminatedencephalomyelitis (ADEM), Addison's disease, an allergy or sensitivity,amyotrophic lateral sclerosis, anti-phospholipid antibody syndrome(APS), arthritis, autoimmune hemolytic anemia, autoimmune hepatitis,autoimmune inner ear disease, autoimmune pancreatitis, bullouspemphigoid, celiac disease, Chagas disease, chronic obstructivepulmonary disease (COPD), diabetes mellitus type 1 (IDDM),endometriosis, fibromyalgia, Goodpasture's syndrome, Graves' disease,Guillain-Barré syndrome (GBS), Hashimoto's thyroiditis, hidradenitissuppurativa, idiopathic thrombocytopenic purpura, inflammatory boweldisease, interstitial cystitis, lupus (including discoid lupuserythematosus, drug-induced lupus erythematosus. lupus nephritis,neonatal lupus, subacute cutaneous lupus erythematosus and systemiclupus erythematosus), morphea, multiple sclerosis (MS), myastheniagravis, myopathies, narcolepsy, neuromyotonia, pemphigus vulgaris,pernicious anaemia, primary biliary cirrhosis, recurrent disseminatedencephalomyelitis (multiphasic disseminated encephalomyelitis),rheumatic fever, schizophrenia, scleroderma, Sjögren's syndrome,tenosynovitis, vasculitis, and vitiligo.

Inflammation as used in the present invention may also comprise amyopathy. Myopathies are caused when the immune system inappropriatelyattacks components of the muscle, leading to inflammation in the muscle.A myopathy includes an inflammatory myopathy and an auto-immunemyopathy. Myopathies include, without limitation, dermatomyositis,inclusion body myositis, and polymyositis.

Inflammation as used in the present invention may also comprise avasculitis. Vasculitis is a varied group of disorders featuringinflammation of a vessel wall including lymphatic vessels and bloodvessels like veins (phlebitis), arteries (arteritis) and capillaries dueto leukocyte migration and resultant damage. The inflammation may affectany size blood vessel, anywhere in the body. It may affect eitherarteries and/or veins. The inflammation may be focal, meaning that itaffects a single location within a vessel; or it may be widespread, withareas of inflammation scattered throughout a particular organ or tissue,or even affecting more than one organ system in the body. Vasculitisinclude, without limitation, Buerger's disease (thromboangiitisobliterans), cerebral vasculitis (central nervous system vasculitis),Churg-Strauss arteritis, cryoglobulinemia, essential cryoglobulinemicvasculitis, giant cell (temporal) arteritis, Golfer's vasculitis,Henoch-Schonlein purpura, hypersensitivity vasculitis (allergicvasculitis), Kawasaki disease, microscopic polyarteritis/polyangiitis,polyarteritis nodosa, polymyalgia rheumatica (PMR), rheumatoidvasculitis, Takayasu arteritis, Wegener's granulomatosis, and vasculitissecondary to connective tissue disorders like systemic lupuserythematosus (SLE), rheumatoid arthritis (RA), relapsingpolychondritis, Behcet's disease, or other connective tissue disorders,vasculitis secondary to viral infection.

Inflammation as used in the present invention may also comprise a skindisorder. Skin disorders include, without limitation, an acne, includingacne vulgaris, a bullous phemigoid, a dermatitis, including atopicdermatitis and chronic actinic dermatitis, an eczema like atopic eczema,contact eczema, xerotic eczema, seborrhoeic dermatitis, dyshidrosis,discoid eczema, venous eczema, dermatitis herpetiformis,neurodermatitis, and autoeczematization, and statis dermatitis,hidradenitis suppurativa, lichen planus, psoriasis including plaqurepsoriasis, nail psoriasis, guttate psoriasis, scalp psoriasis, inversepsoriasis, pustular psoriasis, erythrodermis psoriasis, and psoriaticarthritis, rosacea and scleroderma including morphea.

Inflammation as used in the present invention may also comprise agastrointestinal disorder. A gastrointestinal disorder includes, withoutlimitation, irritable bowel disease, an inflammatory bowel diseaseincluding Crohn's disease and an ulcerative colitis like ulcerativeproctitis, left-sided colitis, pancolitis and fulminant colitis.

Inflammation as used in the present invention may also comprise acardiovascular disease. When LDL cholesterol becomes embedded inarterial walls, it can invoke an immune response. Chronic inflammationeventually can damage the arteries, which can cause them to burst.Cardiovascular disease is any of a number of specific diseases thataffect the heart itself and/or the blood vessel system, especially theveins and arteries leading to and from the heart. There are more than 60types of cardiovascular disorders including, without limitation, ahypertension, endocarditis, myocarditis, heart valve dysfunction,congestive heart failure, myocardial infarction, a diabetic cardiacconditions, blood vessel inflammation like arteritis, phlebitis,vasculitis; arterial occlusive disease like arteriosclerosis andstenosis, inflammatory cardiomegaly, a peripheral arterial disease; ananeurysm; an embolism; a dissection; a pseudoaneurysm; a vascularmalformation; a vascular nevus; a thrombosis; a thrombphlebitis; avaricose veins; a stroke. Symptoms of a cardiovascular disorderaffecting the heart include, without limitation, chest pain or chestdiscomfort (angina), pain in one or both arms, the left shoulder, neck,jaw, or back, shortness of breath, dizziness, faster heartbeats, nausea,abnormal heartbeats, feeling fatigued. Symptoms of a cardiovasculardisorder affecting the brain include, without limitation, suddennumbness or weakness of the face, arm, or leg, especially on one side ofthe body, sudden confusion or trouble speaking or understanding speech,sudden trouble seeing in one or both eyes, sudden dizziness, difficultywalking, or loss of balance or coordination, sudden severe headache withno known cause. Symptoms of a cardiovascular disorder affecting thelegs, pelvis and/or arm include, without limitation, claudication, whichis a pain, ache, or cramp in the muscles, and cold or numb feeling inthe feet or toes, especially at night.

Inflammation as used in the present invention may also comprise acancer. Inflammation orchestrates the microenvironment around tumors,contributing to proliferation, survival and migration. For example,fibrinous inflammation results from a large increase in vascularpermeability which allows fibrin to pass through the blood vessels. Ifan appropriate procoagulative stimulus is present, such as cancer cells,a fibrinous exudate is deposited. This is commonly seen in serouscavities, where the conversion of fibrinous exudate into a scar canoccur between serous membranes, limiting their function. In anotherexample, a cancer is an inflammatory cancer like a NF-κB-driveninflammatory cancer.

Inflammation as used in the present invention may also comprise apharmacologically-induced inflammation. Certain drugs or exogenicchemical compounds are known to affect inflammation. For example,Vitamin A deficiency causes an increase in an inflammatory response.Certain illicit drugs such as cocaine and ecstasy may exert some oftheir detrimental effects by activating transcription factors intimatelyinvolved with inflammation (e.g. NF-κB).

Inflammation as used in the present invention may also comprise aninfection. An infectious organism can escape the confines of theimmediate tissue via the circulatory system or lymphatic system, whereit may spread to other parts of the body. If an organism is notcontained by the actions of acute inflammation it may gain access to thelymphatic system via nearby lymph vessels. An infection of the lymphvessels is known as lymphangitis, and infection of a lymph node is knownas lymphadenitis. A pathogen can gain access to the bloodstream throughlymphatic drainage into the circulatory system. Infections include,without limitation, bacterial cystitis, bacterial encephalitis, pandemicinfluenza, viral encephalitis, and viral hepatitis (A, B and C).

Inflammation as used in the present invention may also comprise a tissueor organ injury.

Tissue or organ injuries include, without limitation, a burn, alaceration, a wound, a puncture, or a trauma.

Inflammation as used in the present invention may also comprise atransplant rejection. Transplant rejection occurs when a transplantedorgan or tissue is not accepted by the body of the transplant recipientbecause the immune system of the recipient attacks the transplantedorgan or tissue. An adaptive immune response, transplant rejection ismediated through both T cell mediated and humoral immune (antibodies)mechanisms. A transplant rejection can be classified as a hyperacuterejection, an acute rejection, or a chronic rejection. Chronic rejectionof a transplanted organ or tissue is where the rejection is due to apoorly understood chronic inflammatory and immune response against thetransplanted tissue. Also included in the term “transplant rejection” isa graft-versus-host disease (GVHD). GVHD is a common complication ofallogeneic bone marrow transplantation in which functional immune cellsin the transplanted marrow recognize the recipient as “foreign” andmount an immunologic attack. It can also take place in a bloodtransfusion under certain circumstances. GVHD is divided into acute andchronic forms. Acute and chronic GVHD appear to involve different immunecell subsets, different cytokine profiles, somewhat different hosttargets, and respond differently to treatment.

Inflammation as used in the present invention may also comprise aTh1-mediated inflammatory disease. In a well-functioning immune system,an immune response should result in a well balanced pro-inflammatory Th1response and anti-inflammatory Th2 response that is suited to addressthe immune challenge. Generally speaking, once a pro-inflammatory Th1response is initiated, the body relies on the anti-inflammatory responseinvoked by a Th2 response to counteract this Th1 response. Thiscounteractive response includes the release of Th2 type cytokines suchas, e.g., IL-4, IL-5, and IL-13 which are associated with the promotionof IgE and eosinophilic responses in atopy, and also IL-10, which has ananti-inflammatory response. A Th1-mediated inflammatory disease involvesan excessive pro-inflammatory response produced by Th1 cells that leadsto chronic inflammation. The Th1-mediated disease may be virally,bacterially or chemically (e.g. environmentally) induced. For example, avirus causing the Th1-mediated disease may cause a chronic or acuteinfection, which may cause a respiratory disorder or influenza.

The extract of the invention or composition comprising an extract of theinvention is typically administered to an individual, for example ahuman or an animal subject.

Animal subjects that may be treated by the extract or composition of theinvention include, but are not limited to, cats, dogs, horses, andcattle (such as sheep and cows).

The disease or disorder to be treated or prevented is typically selectedfrom the group(s) consisting of osteoarthritis (OA), rheumatoidarthritis, juvenile idiopathic arthritis, spondyloarthropathies likeankylosing spondylitis, reactive arthritis (Reiter's syndrome),psoriatic arthritis, enteropathic arthritis associated with inflammatorybowel disease, Whipple disease and Behcet disease, septic arthritis,gout (also known as gouty arthritis, crystal synovitis, metabolicarthritis), pseudogout (calcium pyrophosphate deposition disease), andStill's disease. Arthritis can affect a single joint (monoarthritis),two to four joints (oligoarthritis) or five or more joints(polyarthritis) and can be either an auto-immune disease or anon-autoimmune disease.

Arthritis is a heterogeneous disease that induces whole-joint damage,such as that found in osteoarthritis (OA). OA is characterized byinflammation of the synovial membrane, modification of the subchondralbone and degradation of the cartilage. Chondrocytes degenerating tohypetrophic chondrocyte until apoptosis will participate along withsynovial and immune cells, to secrete prostaglandins and interleukin1beta (IL1b) leading do cartilage catabolism. Once homeostasis isdisrupted, matrix degradation becomes inevitable. Indeed, overexpressionof matrix metalloproteinases (MMPs) and metalloproteinase withthrombospondin motifs (ADAMTS), as well as a decrease in the tissueinhibitor of metalloproteinases (TIMPs) will degrade the matrix.Furthermore, the overexpressed cytokines inducing an increasedproduction of nitric oxide (NO), prostaglandin E2 (PGE2) andleukotrienes will provoke chondrocyte apoptosis. Cartilage matrixdegradation products will then be released into the synovial fluid andwill exacerbate inflammation, leading to infiltration of innate immunecells into joint tissues (synovium and IFP) and secretion ofinflammatory mediators. All these mechanisms of action will lead toadvanced OA, in which articular cartilage loss is initiated viafibrillation of the superficial zone followed by cartilage damage.

As used herein, the term “treatment” (and, similarly, “treating”) takesits normal meaning in the field of medicine. In particular, the term mayrefer to achieving a reduction in the severity of one or more clinicalsymptom associated with the disease or disorder (e.g. the fungalinfection), as may be determined using techniques known to those skilledin the art (for example, by a medical physician) and/or to slowing theprogression of the disease or disorder (i.e. increasing the amount oftime taken for the disease or disorder to progress to a more severestate, e.g. when compared to the time expected to be taken in a patientnot so treated).

As used herein, the term “prevention” (and, similarly, “preventing”)includes references to the prophylaxis of the disease or disorder (andvice-versa). In particular, the term may refer to achieving a reductionin the likelihood of the patient (or healthy subject) developing thecondition (for example, at least a 10% reduction, such as at least a20%, 30% or 40% reduction, e.g. at least a 50% reduction).

For the avoidance of doubt, in the context of the present invention, theterms “treating” and “preventing” include the therapeutic, orpalliative, treatment of subjects/patients in need of, as well as theprophylactic treatment and/or diagnosis of patients which aresusceptible to, the relevant disease states.

As used herein in relation to medical conditions, the term “reducing”may refer to making the observed quantity smaller or decrease in size.

As used herein, the terms “subject” and “patient” may be usedinterchangeably and include mammalian species (particularly humans).

EXAMPLES

The present invention will be further described by reference to thefollowing, non-limiting examples.

Example 1: Typical Extraction of Rubus idaeus Extract

The extract of the invention is typically prepared as follows:

Rubus idaeus (aerial part: leaves/stems) was ground so that theparticles could fit through a 4 mm mesh and the ground material mixedwith EtOH/water (30% ethanol in water) in a reactor. The ratio ofsolvent:plant material was 10:1 (v/w). The raw material was thenextracted under reflux with agitation for about 1 hour 30 minutes.

After the extraction, the mixture was filtered using a filter of 25micron in order to separate the liquid from the solid phase (cake).

The extraction step was repeated, and the resulting filtrates combined.The solid phase was discarded.

The combined filtrates were then concentrated under vacuum (e.g. 0.8 Pa)to 50% DM.

The resulting extraction solid was referred to as the “native extract.”

The native extract was then spray dried to a % DM content of about 97%.

Example 2: Determination of Total Phenol, Sanguiin H6 and LambertianninC Dosage in Rubus idaeus Extract

The amount of various compounds, including phenolic compounds such asellagitannins, lambertianin C and sanguiin h6, ellagic acid compoundssuch as chlorogenic acid and allagic acid, flavonoids compounds such asquercetin-3-O-xyl-glucoronide, hyperoside, quercetin and kaempferol weredetermined in Rubus idaeus extract using the following HPLC method.

Quantification of target compounds was performed on an HPLC Agilent 1100HPLC system equipped with a UV detector. The separation of compounds wascarried out on Atlantis T3 C₁₈ 150 mm×3.0 mm; 3 μm set at 32° C. Themobile phase consisted of acetonitrile/water (50:50)+0.1% formic acid(eluent A) and water+0.1% formic acid (eluent B).

The gradient for eluent A was as follow: 0 min, 12%; 10 min, 20%; 30min, 43%; 40 min, 100%; 55 min, 100%.

The gradient for eluent B was the difference between 10% and eluent Agradient.

The total run time was 50 mm Injection volume was 2 μL and flow rate was0.6 mL/min.

UV monitoring was performed at 280 nm for phenolic compounds detection,325 nm for ellagic compounds detection and 348 nm for flavonoidscompounds. The amount of target compounds were quantified by comparingpeak area of the sample with peak area of reference compound of knownconcentration.

The total phenolic content were determined by using the Folin-Ciocalteuassay as described in Singleton, V. L., & Rossi, J. A. (1965).Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acidreagents. American journal of Enology and Viticulture, 16(3), 144-158.

TABLE 1 the analytic results of an aqueous rubus Idaeus extract and arubus Idaeus extract obtained using 30% ethanol in water. Compoundst_(R) (min) EtOH 30% H₂0 100% Phenolics compounds 280 nm EllagitanninC68H48O44* 5.21 0.21 0.13 Ellagitannin C68H48O44* 6.62 0.05 0.05Ellagitannin C68H48O44* 7.3 0.23 0.22 Ellagitannin C68H48O44* 8.36 0.310.24 Ellagitannin C68H48O44* 12 0.26 0.07 Ellagitannin C68H48O44* 14.10.09 0.02 Ellagitannin C68H48O44* 14.54 0.1 0.04 Geraniin 15.47 0.0215.47 0.02 Ellagitannin C68H48O44* 16.64 0.13 0.003 EllagitanninC68H48O44* 17.26 0.19 Ellagitannin C68H48O44* 18.42 0.35 0.17 SanguiinH10* 18.84 0.003 Ellagitannin C68H48O44* 19.77 0.33 EllagitanninC68H48O44* 20.41 0.4 0.3 Ellagitannin C68H48O44* 20.71 0.16 0.17Ellagitannin C68H48O44* 21.19 0.16 0.01 Lambertianin C* 21.75 2.49 0.66Sanguiin H6* 22.41 4.52 1.37 TOTAL (%) 10.00 3.46 Hydroxycinnamic acidand ellagic acid compounds 325 nm Chlorogenic acid 5.66 0.05 0.05Chlorogenic acid 7.81 0.11 0.12 Chlorogenic acid 9.05 0.06 0.07Chlorogenic acid 9.4 0.1 0.09 Chlorogenic acid 9.87 0.05 0.05Chlorogenic acid 10.42 0.05 Chlorogenic acid 11.62 0.32 0.3 p-coumaricacid 12.92 0.09 0.14 Chlorogenic acid 14.98 0.12 0.18 Ellagic acid 24.690.49 0.27 Ellagic acid 1.44 1.27 Flavonoids compounds 348 nmQuercetin-3-O-xyl-glucuronide 23.03 0.22 0.24 Hyperoside 24.69 0.35 0.21Kaempferol glucoside 25.57 0.21 0.18 Quercetin-3-O-glucuronide 26.141.06 1 Quercetin C27H28O16 27.53 0.45 0.41 Kaempferol glucoside 29.490.55 0.52 Kaempferol 3-O-glucuronide 30.16 0.25 0.23 Kaempferol3-O-galactoside 30.68 0.13 0.12 TOTAL (%) 3.22 2.91 % polyphenols byfolin Ciocalteu method H20 100% 19.07 EtOH 30% 23.11 *refers todifferent ellagitannin compounds from the same family

Example 3: The Effect of Rubus idaeus on the Resolution Phase ofInflammation

Peripheral blood mononuclear cells (PBMCs) were seeded and allowed tosediment for 1 h. After 1 h, Rubus idaeus extract was added andincubated for an extra hour. At the end of this time, an inflammatoryresponse was induced by PMA/A23187 in presence of PUFA (DHA/EPA at 1μg/ml each), the reaction time was for 1 hour. The culture supernatantswere then removed for analysis of the lipid mediators.

Each supernatant was concentrated by solid phase extraction (SPE) andanalyzed in LC/MS. An analytical method by coupling liquidchromatography and mass spectrometry (LC/MS) was used in order toquantify the bio-active lipids. The LC/MS analyzes were performed on anLC 1290 Infinity (Agilent Technologies) chain coupled to a 6460 TripleMass Spectrometer Quad LC/MS (Agilent Technologies) equipped with anelectrospray ionization source (Jet stream technology) operating in thenegative world. The chromatographic separations were carried out on aZorBAX SB-C18 column (2.1×50 mm*1.8 μm).

As shown in Table 2, the analysis revealed that the Rubus idaeus extractincreases the secretion of 5-HETE and 12-HETE, intermediaries oflipoxins synthesis implicated into the resolution of inflammation.

TABLE 2 the effect of Rubus idaeus extract on the mechanism ofresolution of inflammation. Dose PGE2 18-HETE 15-HETE 17-HDOHE 14-HDOHE12-HETE 5-HETE Ctrl PBMC −91.2 −100 −71.5 −98 −76.9 −78.6 −99.7PMA/A23187 + 0.0 0.0 0.0 0.0 0.0 0.0 0.0 AGPI Rubus 20 μg/ml −2.8 8.8−0.9 3.3 2.6 11.7 23.6 Idaeus

Example 4: The Effect of Rubus idaeus Extract on Joint Swelling AnimalModel of Arthritis

This study was designed to evaluate the ability of Rubus idaeus extractto treat the inflammatory process involved in an arthritis mBSA animalmodel.

The protocol and more particularly the animal model described below, wasbased on the publication reference Y H Yang et al, Arthritis andRheumatism, 2004, in which the authors studied the effect of a receptoragonist of the resolution.

The mice used in these experiments were 6 weeks old C57/BL6 females.They were divided in cages of 3 animals and subjected to a normal diet(Safe—ref A04 which guaranty 16.1% of protein, 3.1% fat, 5.1% ashes and3.9% cellulose for a total of 2.9 kcal/g eaten) and fluid intake adlibitum throughout the experiment. Before the experiment, they hadundergone a phase of acclimatization.

Two weeks before the first induction of mBSA, and throughout theduration of the experiment, the mice were divided into 4 groups andreceived (i) PBS/PBS (negative control); (ii) PBS/mBSA (positivecontrol); (iii) a treatment of 30 mg/Kg of Rubus idaeus extract(D30/mBSA) or (iv) a treatment of 120 mg/Kg of Rubus idaeus extract(D120/mBSA). Treatments were administered by gavage once per day.

Induced arthritis methylated albumin (mBSA) was developed in the mice.Induction to mBSA consists in carrying out a first immunization by themBSA to 1 mg/ml in complete Freud's adjuvant with subcutaneous injection(200 μl). A week later, the animals were again injected with a cocktailof the same composition in the tail (100 μl) and arthritis was inducedtwo weeks after using a 10 μl injection of mBSA (3 mg/ml diluted in PBS)or PBS alone as a control directly in each of the joints of the backlegs. All injections were performed under general anesthesia withVetoflurane.

After injection of mBSA into the joint of the hind legs, their swellingwas measured using calipers at 2, 4, 6, 24, 48 and 72 hours postinjection. The measurement was taken at the width and thickness of thepaw of the animal.

The results showed that mBSA injection induced an increase in pawthickness which became significantly different from the control paws(PBS/PBS). The increase was visible 24 hours after injection up to 72hours (end of measurement).

After 6 hours, 120 mg of Rubus idaeus extract significantly reduced thepaws thickness compared to PBS/mBSA group. Overall, when mice areforce-fed with Rubus idaeus extract, the thickness of the lower paws wasnot significantly different than the paws thickness of the PBS/PBS northan the positive control one (PBS/mBSA). Therefore, as shown in FIG. 1,Rubus idaeus extract prevents the appearance of the inflammation byreducing its virulence.

These results demonstrated a beneficial effect of Rubus idaeus extracton the articular swelling.

Example 5: The Effect of Rubus Idaeus Extract on IL-6, IL-Lb and TNF-αPlasmatic Level in Animal Model of Arthritis

Using the same animals as in Example 4, 72 h after the Rubus idaeusinjection and before euthanasia, blood was sampled at the renal arteryusing a sterile syringe without endotoxins. Plasma was separated andsamples were then frozen for subsequent analysis.

The cytokine analysis was performed using the Luminex 100IS camera. Thisdevice is designed to the acquisition and analysis of microdosingmultiplex tests, which uses Luminex xMAP technology (Multi ProfilingAnalysis) with microspheres different fluorescence, allowingsimultaneous quantification up to 100 parameters in a single well in amicrovolume. The cytokines of interest were: IL-6, IL-1b and TNF-α whichare known to play a central role in joint disorders

The results demonstrated that PBS/mBSA animals have a level of IL-6 inplasma statistically higher than the control animals PBS/PBS as well asa higher amount of IL-1b and TNF-α.

As shown in FIG. 2, Rubus idaeus extract reversed the inflammatoryprocess. Indeed, D30/mBSA prevented the released of the statisticallysignificant increase of IL-6 as measured in PBS/mBSA compared toPBS/PBS. Rubus idaeus extract also had a tendency to reduce TNF-alevels.

These results demonstrated an anti-inflammatory effect of the Rubusidaeus extract.

Example 6: The Effect of Rubus idaeus Extract on Bioactive LipidCompounds Plasmatic Level in Animal Model of Arthritis

Using the same animal as in Example 4, blood sample were analyzed tomeasure the bioactive compounds level from arachidonic acid (AA),eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA) which areclearly identify into the resolution of inflammation.

Plasmas were thawed on ice and the lipid compounds were concentrated bysolid phase extraction (SPE), taken up in methanol before spectrometricanalysis. The analytical method used consists in separating the variousanalytes by high pressure liquid chromatography depending of theirretention time and to quantify them by mass spectrometry.

Analysis was carried out on an LC 1290 Infinity chain (AgilentTechnologies) coupled with a 6460 Triple Quad LC/MS (AgilentTechnologies) mass spectrometer equipped with an electrospray ionizationsource (Jet stream technology) operating in a negative world.Chromatographic separations were performed on a Zorbax SB-C18. Accordingto the method described by Baillif et al. In: LC-MS/MS method for rapidand concomitant quantification of pro-inflammatory and pro-resolvingpolyunsaturated fatty acid metabolites. J Chromatogr B Analyt TechnolBiomed Life Sci. 2013; 932: 123-33.

The results (as shown in FIG. 3) showed that 12-HETE level after Rubusidaeus intake was statistically significantly increased compared toPBS/mBSA. Furthermore, Rubus idaeus intake restored, baseline level of14-HDOHE and 7 (R) MAR1 in sick animals compared to PBS/mBSA. Both ofthese lipids are secondary metabolite from DHA degradation which areresponsible to promote phagocytosis of particles apoptotic inflammatorymacrophages.

14-HDOHE is a precursor of the 7 (R) MAR1 and 7 (R) MAR1 and isdescribed as one of the most effective agents in the resolution inparticular by promoting phagocytosis of particles apoptotic inflammatorymacrophages. Therefore, the return to basal endogenous production rateindicates that the Rubus idaeus can trigger the natural ability toproduce these molecules to fight inflammation, which is the foundationof the concept of resolution.

Example 7: the Effect of Rubus idaeus Extract on Joint HistologicalInflammation in Animal Model of Arthritis

Using the same animals as used in Example 4, this experiment was set upto determine whether the changes observed in the paw swelling as well asin cytokines and bioactive lipids secretion, could lead to improvedtissue parameters. To do so right legs joints of the animals werecollected, microtomed and stained to evaluate the histological lesions.

The results (as shown in FIG. 7) demonstrated a statically significantincreased inflammation with penetration of lymphocytes, plasma cells,polymorphonuclear neutrophils and histiocytes in all the PBSA-treatedanimals. The synovial membrane was also statistically significantlymarked with increased inflammation in PBSA-treated animal, which was notthe case when treated with Rubus idaeus extract and more specificallywith at a dose of 30 mg/Kg (D30/mBSA) and 120 mg/Kg D120/mBSA,demonstrating a preventive effect of Rubus idaeus extract on thesynovial inflammation. In the periosteum a tendency of increasedinflammation was observed in all the mBSA treated group. Results on theoverall inflammation revealed that animals treated with Rubus idaeusextract showed a statically significant decrease score compared toPBSA-treated animals.

Example 8: The Effect of Rubus idaeus Extract Inflammatory Response onChondrocytes Stimulated by IL1

Chondrocytes were extracted from tibia and femoral epiphyses and femoralheads of 5-6 day old mice (C57BI/6 strain). The isolation ofchondrocytes from the cartilaginous matrix was achieved by the action ofthe libertase (100 μg/ml, Roche Applied Science) for 24 hours. The cellswere then seeded at a density of 200,000 cells/ml in 12-well plates at arate of 1 mL per well as a duplicate cultured in DMEM medium (Gibco®,Invitrogen) supplemented with 10% FCS, 2% Glutamine (Gibco®, Invitrogen)and 1% penicillin/streptomycin.

After confluence of the chondrocytes (4-6 days of culture), the latterwere cultured in medium without SVF 24 h, activated by IL1 (1 ng/ml) 24h and then cultured in the presence of one of the 4 concentrations (10μg/mL, 20 μg/mL, 40 μg/mL or 100 μg/mL) of 30% ethanolic Rubus idaeusextracts or aqueous Rubus idaeus extract or 5/50 of both extracts for anadditional 24 h. These doses were defined in preliminary experimentsevaluating the impact of extracts on markers of inflammation fromperipheral blood mononuclear cells (PBMC) such as described into example2.

At the end of the culture (IL1 24 h and 24 h with the Rubus idaeusextracts), several experiments will be performed to analyze gene orprotein expression.

For gene expression, the chondrocyte cultures were stopped by Trizol andRNA extraction was performed to analyze gene expression by quantitativePCR markers of catabolic (MMP3, MMP13, ADAMTS4, Adamts5), anabolicmarkers (Collagen Type 2, Aggrecan, Sox9), hypertrophy markers (collagenX, VEGF) and inflammation (COX2).

These experiments were repeated for a cell survival assay using the MTTassay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium) and totest apoptosis by TUNEL (Apoptag, Apoptosis Detection Kit (Millipore)).

Example 9: Inhibition of Granzyme B

The activity of Granzyme B was tested over time in the presence of 0.03%Rubus idaeus 30% ethanol extract, 0.02% Rubus idaeus 30% ethanolextract, 0.01% Rubus idaeus 30% ethanol extract, and a known Granzyme Binhibitor (positive control). A negative control was also set up.

As shown in FIG. 4, each of the Rubus extracts inhibited the activity ofGranzyme B.

Example 10: Comparison of Granzyme B Inhibition Between an Aqueous RubusExtract and a 30% Ethanolic Extract

The inhibitory activity of a 0.01% and a 0.03% Rubus idaeus extractobtained using 30% ethanol was compared to the inhibitory activity of a0.01%, 0.02%, 0.03% and 0.05% Rubus idaeus extract obtained using wateronly as the solvent.

As shown in FIGS. 5 and 6, the activity of the extract obtained using30% ethanol was significantly higher than the activity of the extractobtained using water only.

1. A liquid or solid oral dosage form comprising a composition fortreating inflammation associated with arthritis or joint swelling, thecomposition comprising a therapeutically effective amount of a Rubusidaeus extract, wherein the extract comprises (i) from about 1% to about40% by weight of phenolic compounds; (ii) from about 0.5% to about 7% byweight of hydroxycimmanic acid and ellagic compounds; and (iii) fromabout 1% to about 15% by weight of flavonoid compounds.
 2. The oraldosage form of claim 1, wherein the solid oral dosage form is selectedfrom the group consisting of hard capsules, soft capsules, tablets,troches, dragees, pills, lozenges, powders, and granules; and whereinthe liquid oral dosage form is selected from the group consisting ofemulsions, elixirs, aqueous suspensions, oily suspensions, solutions,and syrups.
 3. The oral dosage form of claim 1, wherein the extract isobtained from the aerial part of Rubus idaeus.
 4. The oral dosage formof claim 3, wherein the aerial part of the Rubus idaeus comprises thestems of the Rubus idaeus.
 5. The oral dosage form of claim 3, whereinthe aerial part of the Rubus idaeus comprises the leaves of the Rubusidaeus.
 6. The oral dosage form of claim 1, wherein the Rubus idaeusextract is derived in the absence was other plants of the Rubus genus.7. The oral dosage form of claim 1, wherein the Rubus idaeus extractcomprises an aqueous extract.
 8. The oral dosage form of claim 1,wherein the Rubus idaeus extract comprises an ethanol extract.
 9. Theoral dosage form of claim 1, wherein the composition comprises afunctional food composition, a pharmaceutical composition, or aveterinary composition.
 10. The oral dosage form of claim 9, wherein thecomposition comprises a pharmaceutical composition comprising apharmaceutically acceptable excipient.
 11. The oral dosage form of claim10, wherein the pharmaceutically acceptable excipient is selected fromadjuvants, carriers, diluents, and combinations thereof.
 12. The oraldosage form of claim 11, wherein the carriers are selected from solidfillers, sterile aqueous solutions, and organic solvents.
 13. The oraldosage form of claim 9, wherein the composition comprises a veterinarycomposition comprising a veterinary acceptable excipient.
 14. The oraldosage form of claim 13, wherein the veterinary acceptable excipient isselected from adjuvants, carriers, diluents, and combinations thereof.15. The oral dosage form of claim 14, wherein the carriers are selectedfrom solid fillers, sterile aqueous solutions, and organic solvents. 16.The oral dosage form of claim 9, wherein the functional food compositionis selected from the group consisting of a feed, a food, a pet food, afeed supplement, a food supplement, and a pet food supplement.
 17. Theoral dosage form of claim 1, wherein the composition can provide theextract in an amount from about 10 mg/day to about 2000 mg/day.
 18. Theoral dosage form of claim 1, wherein the composition can provide theextract in an amount from about 500 mg/day to about 1500 mg/day.
 19. Theoral dosage form of claim 1, wherein the composition can provide theextract in an amount of about 1000 mg/day.
 20. The oral dosage form ofclaim 1, wherein the composition comprises 10 mg, 20 mg, 30, mg, 40 mg,50 mg, 60 mg, 70 mg, 80 mg, 100 mg, 250 mg, 500 mg, 750, 1000 mg, 1500mg, or 2000 mg of the extract.